Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. ABBV

Go back to Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat

Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs

March 15, 2024 3:51 AM EDT

Goldman Sachs analyst Corinne Jenkins raised the price target on Geron Corporation (NASDAQ: GERN) to $5.00 (from $4.00) while maintaining a Buy rating.

The analyst comments "

We expect GERN to trade higher tomorrow (+85-90% in after hours trading) following the FDA's Advisory... More

Geron Corp (GERN) Halted, News Pending

March 14, 2024 6:55 AM EDT

Geron Corp (NASDAQ: GERN) Halted, News Pending

... More